Factors underlying COVID-19 booster vaccine uptake among adults in Belgium.
COVID-19 Vaccines
COVID-19 breakthrough infections
COVID-19 reinfection
COVID-19 vaccine booster shot
Public health surveillance
Vaccination coverage
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
11 Nov 2023
11 Nov 2023
Historique:
received:
23
06
2023
accepted:
31
10
2023
medline:
13
11
2023
pubmed:
12
11
2023
entrez:
11
11
2023
Statut:
epublish
Résumé
This study aimed to investigate factors influencing the uptake of first and second COVID-19 booster vaccines among adults in Belgium, particularly age, sex, region of residence and laboratory confirmed COVID-19 infection history. A binomial regression model was used with having received the first or second booster as outcome and age, sex, region of residence and infection history as fixed variables. Among adults, there was generally a higher uptake to receive the first booster among older age groups compared to younger ones. Females, individuals residing in Flanders and those with no previous COVID-19 infection were more likely to receive the first booster. For the second booster, the same age trend was seen as for the first booster. Males, individuals residing in Flanders and those who tested positive for COVID-19 once after first booster were more likely to receive the second booster. Individuals with multiple positive COVID-19 tests before and after primary course or first booster were less likely to receive the subsequent booster dose compared to COVID-naïve individuals. This information could be used to guide future vaccination campaigns during a pandemic and can provide valuable insights into booster uptake patterns.
Identifiants
pubmed: 37951923
doi: 10.1186/s13104-023-06608-4
pii: 10.1186/s13104-023-06608-4
pmc: PMC10640742
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
328Subventions
Organisme : Belgian Federal Authorities
ID : LINK-VACC
Informations de copyright
© 2023. The Author(s).
Références
PLoS One. 2022 Sep 22;17(9):e0274529
pubmed: 36136997
J Epidemiol Community Health. 2022 Jul;76(7):646-652
pubmed: 35470259
Vaccine. 2021 Oct 8;39(42):6256-6261
pubmed: 34544601
Dan Med J. 2022 Dec 7;69(1):
pubmed: 34913428
BMC Public Health. 2022 Sep 14;22(1):1745
pubmed: 36104675
Lancet Reg Health Eur. 2022 Mar;14:100317
pubmed: 35132400
Hum Vaccin Immunother. 2023 Dec 31;19(1):2188857
pubmed: 36941785
Med Decis Making. 2023 Feb;43(2):239-251
pubmed: 36404766
Vaccines (Basel). 2022 Mar 10;10(3):
pubmed: 35335057
Appl Psychol Health Well Being. 2023 Nov;15(4):1293-1318
pubmed: 36748440
Lancet Reg Health Eur. 2022 May 29;18:100414
pubmed: 35651957
Prev Med. 2022 Nov;164:107269
pubmed: 36162486
Vaccine. 2022 Nov 2;40(46):6640-6648
pubmed: 36210254
BMC Public Health. 2023 Feb 24;23(1):391
pubmed: 36829138
Hum Vaccin Immunother. 2023 Dec 31;19(1):2188856
pubmed: 36988622